NEW YORK, July 31, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Agenus Inc. (NASDAQ: AGEN), RXi Pharmaceuticals
Corporation (NASDAQ: RXII), Nektar Therapeutics (NASDAQ: NKTR),
Genetic Technologies Ltd (NASDAQ: GENE) and Agios Pharmaceuticals
Inc. (NASDAQ: AGIO). Free research report on Agenus can be accessed
at https://www.EquityResearchInstitute.com/reports?keyword=AGEN. On
Thursday, July 30, 2015, the NASDAQ
Composite ended at 5,128.79, up 0.33%, the Dow Jones Industrial
Average edged 0.03% lower, to finish the day at 17,745.98, and the
S&P 500 closed flat at 2,108.63. During the session four out of
nine sectors ended in positive. Register for your complimentary
reports at the links given below.
On Thursday, shares in Agenus Inc. ended the session 1.82%
higher at $8.39. The stock reported a
trading volume of 1.03 million shares, below its three months
average volume of 1.72 million shares. Although, Agenus Inc.'s
shares have declined 2.78% in the last one month, it has surged
26.93% in the previous three months and 111.34% on YTD basis. The
stock is trading 49.39% above its 200-day moving average. Moreover,
shares of Agenus Inc. have a Relative Strength Index (RSI) of
44.32. Sign up and read the free notes on AGEN at:
https://www.EquityResearchInstitute.com/reports?keyword=AGEN
RXi Pharmaceuticals Corp.'s stock lost 5.30%, to close the day
at $0.41. The stock recorded a
trading volume of 0.86 million shares, much below its three months
average volume of 1.83 million shares. Over the last one month and
over the past three months, RXi Pharmaceuticals Corp.'s shares have
declined 16.12% and 36.87%, respectively. Furthermore, the stock
has lost 74.31% since the start of this year. The company's shares
are trading 13.12% below their 50-day moving average. Additionally,
RXi Pharmaceuticals Corp. has an RSI of 36.75. The complimentary
notes on RXII can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=RXII
On Thursday, shares in Nektar Therapeutics recorded a trading
volume of 1.10 million shares, lower than their three months
average volume of 1.83 million shares. The stock ended the day
1.31% higher at $12.33. Shares of the
company traded at a PE ratio of 72.53. Although, Nektar
Therapeutics' stock has surged 29.52% in the previous three months,
it has lost 1.44% in the last one month and 20.45% on YTD basis.
The company is trading above its 50-day moving average by 2.78%.
Furthermore, shares of Nektar Therapeutics have an RSI of 50.46.
Register for free on Equity Research Institute and access the
latest research on NKTR at:
https://www.EquityResearchInstitute.com/reports?keyword=NKTR
Genetic Technologies Ltd's stock lost 2.15%, to close Thursday's
session at $3.19. The stock recorded
a trading volume of 0.14 million shares, below its three months
average volume of 0.63 million shares. Over the last one month and
since the beginning of 2015, Genetic Technologies Ltd.'s shares
have surged 4.93% and 63.59%, respectively. However, the stock has
declined 27.83% in the previous three months. The company is
trading 11.01% and 6.79% below its 50-day and 200-day moving
averages, respectively. Furthermore, Genetic Technologies Ltd's
stock has an RSI of 45.44. The complete research on GENE is
available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=GENE
Agios Pharmaceuticals Inc.'s stock finished Thursday's session
1.26% lower at $108.91. A total of
0.33 million shares were traded, which was below its three months
average volume of 0.62 million shares. Over the last one month and
since the start of this year, Agios Pharmaceuticals Inc.'s shares
have fallen by 2.01% and 2.79%, respectively. However, the stock
has gained 17.94% in the previous three months. The company's
shares are trading above their 200-day moving average by 3.34%.
Agios Pharmaceuticals Inc.'s stock has an RSI of 42.88. Free
in-depth research on AGIO is available at:
https://www.EquityResearchInstitute.com/reports?keyword=AGIO
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com